One is up and one is down—we like both

Article Excerpt

Medical device maker Enovis (formerly called Colfax) spun off its non-medical businesses in 2022 as a separate firm called ESAB. So far, the former parent is down 19% while the new firm is up an impressive 113%. We feel Enovis will turn around given it benefits from the aging population. ESAB’s outlook is also positive given increased government spending on infrastructure projects. ENOVIS CORP. $56 is a spinoff buy. The company (New York symbol ENOV, Manufacturing sector; Shares outstanding: 54.6 million; Market cap: $3.1 billion; No dividend paid; Takeover Target Rating: Medium; www.enovis.com) makes over 1,000 medical devices for reconstructive surgery, rehabilitation, pain management and physical therapy. The company was formerly known as Colfax Corp. On April 4, 2022, Colfax completed the spinoff of ESAB Corp. (see right). Shareholders received one ESAB share for every three shares held in Enovis. As part of the spinoff, Colfax changed its name to Enovis. It also consolidated its shares on a 1-new-for-3-old basis. Enovis retained 10% of ESAB’s stock. In November…